: A female patient underwent a total ovario-hysterectorny for metastasis after a gastrectomy , and disseminated peritoneal metastasis was detected.
Introduction
Cancer treatments include surgery, radiotherapy, chemotherapy, and immunotherapy. However, terminal or recurrent cancers do not respond to these treatments and are difficult to treat ; therefore , symptomatic therapy must be selected.
Recent attention to chemothermotherapy is showing that it is an effective treatment for cancer ') . This is a report of a patient who received chemothermotherapy, as a result of which her QOL improved and her life was prolonged. In addition, the immunological effects of the treatment are reported . Physical examination on admission : height, 150 cm ; body weight, 46 kg ; and blood pressure, 110/ 70 mmHg. Her face exhibited pallor, and malnutrition without jaundice was observed. In the thoracic region, there were no abnormal physical findings, and, in the abdomen, the bulge of a surgical scar and pressure pain were noted. In the bilateral lower limbs, cachexia, including marked edema, was observed. Laboratory data on admission showed normocytic normochromic anemia, hypoproteinemia, hypoalbuminemia, and hypocholesterolemia. The level of alkaline phosphatase was increased ; however, the levels of tumor markers were within the normal ranges (Table I) . Computed tomography (CT) revealed dilatation of the upper abdomen, a solid mesenteric structure in the right lower abdomen, and a funicular structure in the pelvis (Fig. 1) . The course of treatment selected included hyperthermia in the upper abdomen (3 times/week, 45 min/set, 1,296 w/set) with a Thermotron RF-8 (Yamamoto Vinyter Co., Ltd., Japan), chemohyperthermia with 10 mg/week of MMC, and total parenteral nutrition (TPN), since oral ingestion was impossible. One month after the start of treatment, abdominal pain, general malaise, abdominal swelling, and cachexia, including marked edema of the lower limbs, gradually subsided. When the total dosage of MMC reached 100 mg, therefore, administration was discontinued due to grade 2 bone marrow suppression, whereas hyperthermia was continued (Fig. 2) . At the end of MMC administration, the CT revealed that the solid structure in the lower abdomen had disappeared and that there had been a marked improvement in the ileus. Passage disorder in the pelvic region remained ( Fig. 1 ). Three weeks after the end of MMC administration, intermittent FP therapy 2) (CDDP : 3 mg/ day, 5 days/week 5-FU : 750 mg/day, 3 days/week), which is a procedure of biochemical modulation (BCM), was started. To treat the passage disorder, hyperthermia in the pelvic region was started 20 days after the start of BCM. Because upper abdominal pain recurred 215 days after admission, the hyperthermia site was switched to the upper abdomen. About one month later, the pain subsided. At about 280 days after admission, gastric juice, which had persisted for a long time, had been completely eliminated, facilitating oral ingestion. Therefore, TPN was discontinued, and the QOL also improved.
Bone marrow suppression was observed, as described with MMC, and a similar treatment was performed.
No serious adverse event occurred, and intermittent FP therapy was eventually discontinued according to the wishes of the patient (Fig. 2) . The passage disorder, which had been discovered through CT at the onset of recurrent upper abdominal pain, had improved markedly within two months of detection (Fig. 3) .
However, the area where the passage disorder had been detected was not enhanced in the CT. In that area, fluorodeoxyglucose-positron emission tomography (FDG-PET) showed that the accumulation had been enhanced at two points, and this finding disappeared within two months of the chemohyperthermia (Fig. 4) .
The levels of ferritin and NK cell activity gradually increased after admission. The ferritin level at 300 days after admission was 260 times higher than it had been on admission.
The NK cell activity also increased from 13.4% to 47.3% (Fig. 5 ).
Hypoalbuminemia and hypocholesterolemia, which were observed on admission, improved to normal levels appruAilllately 300 days after admission ; however, there were no changes in the alkaline phosphatase level (Table I) .
Discussion
Currently, symptomatic therapy is performed to treat terminal gastric cancer with disseminated peritoneal metastasis ; however, the prognosis is poor.3) Recently, Nakabayashi et al.4) reported a new treatment ; they inserted a 24-F silicon tube into the peritoneal cavity during a gastrectomy for progressive gastric cancer with peritoneal dissemination. The chemothermotherapy group, in which intraperitoneal administration of CDDP was combined with thermotherapy 2 weeks after surgery , showed a better prognosis than the surgery group. However, when intestinal adhesion related to gastrectomy and additional surgery or ileus related to disseminated peritoneal metastasis are observed, as in this case, In addition, the symptoms subsided 2 months after the start of treatment, and FDG-PET showed that the accumulation had disappeared, suggesting that this procedure is more accurate than CT for evaluating the treatment response. Thermotherapy increases NK cell activity,14) which is considered its indirect effect.
In the present patient, NK cell activity also increased, although bone marrow suppression was observed during intermittent FP therapy. It was speculated that the thermal effects of this procedure may have overcome the influence of bone marrow suppression and that the improvement in parasympathetic actions may have been related to the improvements in the clinical symptoms.
It also resulted in an increase of the relaxation period, which persistently increased the NK cell activity and exhibited antitumor effects.
It appears then that the intermittent FP therapy led to the decay of the cancer cells via the direct effects of thermotherapy, in other words, it had tumoricidal effects, and that ferritin was released into the blood, resulting in a gradual increase.
In MMC therapy, there were no increases in NK cell activity or in the ferritin level. Concerning NK cell activity, MMC-related bone marrow suppression may have been involved ; however, concerning the ferritin level, an etiological factor is unclear, although the influence of MMC cannot be ruled out.
Chemothermotherapy by systemic administration of anticancer agents to patients with terminal gastric cancer, in whom it was expected that multiple drug resistance would make the prognosis poor, exhibited antitumor effects, improved the QOL, and has prolonged a patient's survival by, so far, 300 days.
In particular, chemothermotherapy by intermittent FP therapy increased the immune capacity, which suggests its usefulness.
